Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

docum	ents given to ASX become ASX's propert	y and may be made public.
Introduc	red 01/07/96 Origin: Appendix 5 Amended 01/07/9	98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12
Name	of entity	
Presc	ient Therapeutics Limited	
ABN		
56 00	6 569 106	
Wo (t	the entity) give ASX the followin	g information
,	1 - All issues	g information.
	ust complete the relevant sections (attac	ch sheets if there is not enough space).
		Tr. II. I
1	*Class of *securities issued or to be issued	Unlisted options
-	N	200 000
2	Number of *securities issued or to be issued (if known) or	300,000
	maximum number which may	
	be issued	
3	Principal terms of the *securities (eg, if options,	Unlisted options exercisable at \$0.092 (9.2
	+securities (eg, if options, exercise price and expiry date; if	cents) per option on or before 6 May 2018, with the following vesting dates:
	partly paid +securities, the	with the following vesting dutes.
	amount outstanding and due dates for payment; if	- 100,000 options vesting on 6 May 2016.
	+convertible securities, the	<ul><li>100,000 options vesting on 6 May 2017.</li><li>100,000 options vesting on 6 May 2018.</li></ul>
	conversion price and dates for	100,000 options vesting on o May 2010.
	conversion)	

01/08/2012 Appendix 3B Page 1

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

4	Do the *securities rank equally in all respects from the date of allotment	The options are not quoted.
	with an existing *class of quoted *securities?	Shares issued on exercise of the options will rank equally with fully paid shares currently on issue.
	<ul> <li>If the additional securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	
5	Issue price or consideration	Nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	The options are being issued to a contractor to the Company in part consideration for provision of consultancy services to the Company.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h <i>in relation to the</i> * <i>securities the subject of this Appendix</i> 3 <i>B</i> , and comply with section 6i	
6b	The date the security holder resolution	28 November 2014
	under rule 7.1A was passed	·
6c	Number of *securities issued without security holder approval under rule 7.1	300,000
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil

Appendix 3B Page 2 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of securities issued under an exception in rule 7.2	Nil	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	LR 7.1 7,612,2 LR 7.1A 5,274,8	
7	Dates of entering *securities into uncertificated holdings or despatch of certificate	27 May 2015	
		<b>_</b>	,
		Number	+Class
8	Number and *class of all *securities quoted on ASX ( <i>including</i> the securities in section 2 if applicable)	48,164,883	Ordinary fully paid shares
9	Number and *class of all *securities not quoted on ASX ( <i>including</i> the securities in section 2 if applicable)	4,583,338	Ordinary shares subject to 12 months escrow until 11 December 2015
		4,385,000	Unlisted Options exercisable @ \$0.10 each, expiring on 12 October 2017.
		2,000,000	Unlisted Options exercisable @ \$0.14 each, expiring on 11 December 2018.
		300,000	Unlisted Options exercisable @ \$0.092 each, expiring on 6 May 2018

<sup>+</sup> See chapter 19 for defined terms.

o1/08/2012 Appendix 3B Page 3

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

#### Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	N/A
	Note: Security holders must be told how their	
	entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
	Amount of any underwriting fee	N/A

Appendix 3B Page 4 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on *security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do *security holders sell part of their entitlements through a broker and accept for the balance?	N/A
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	N/A

oı/o8/2012 Appendix 3B Page 5

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3	В
New issue a	announcement

33	+Desp	oatch date	N/A
Part	3 - Q	uotation of securitie	S
You ne	ed only o	complete this section if you are ap	plying for quotation of securities
34	Type (tick o	of securities one)	
(a)		Securities described in Part 1	
(b)		All other securities	
			nd of the escrowed period, partly paid securities that become fully paid, in restriction ends, securities issued on expiry or conversion of convertible
Entiti	es tha	t have ticked box 34(a)	
Addi	tional	securities forming a new	class of securities
Tick to docum		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the he number and percentage of additional *securities
36		+securities setting out the nu 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000	securities, a distribution schedule of the additional amber of holders in the categories
37		A copy of any trust deed for	the additional <sup>+</sup> securities

Appendix 3B Page 6 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Entities that have ticked box 34(b)			
38	Number of securities for which †quotation is sought		
39	Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?		
	If the additional securities do not rank equally, please state:  1. the date from which they do  2. the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  3. the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)	Number	+Class

oı/o8/2012 Appendix 3B Page 7

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here

(Company secretary)

Date: 27 May 2015

Print name:

Melanie Leydin

== == == ==

Appendix 3B Page 8 o1/08/2012

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B - Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	28,047,369 (post consolidation)	
<ul> <li>Add the following:</li> <li>Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> <li>Subtract the number of fully paid ordinary securities cancelled during that 12 month period</li> </ul>	15,000,000 (post consolidation) – 19 May 2014 3,000,000 (post consolidation) – 30 May 2014 847 – 5 December 2014 6,700,005 – 11 December 2014	
"A"	52,748,221	

01/08/2012 Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15 [Note: this value cannot be changed]
Multiply "A" by 0.15	7,912,233
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	300,000 - 14 May 2015
<ul> <li>Under an exception in rule 7.2</li> </ul>	
Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	300,000
Step 4: Subtract "C" from ["A" x "L placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	7,912,233
Note: number must be same as shown in Step 2	
Subtract "C"	300,000
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.15] – "C"	7,612,233
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 10 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
52,748,221		
"D"  0.10  Note: this value cannot be changed		
5,274,822		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Nil		

01/08/2012 Appendix 3B Page 11

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	5,274,822	
Note: number must be same as shown in Step 2		
Subtract "E"	-	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	5,274,822	
	[Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 12 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.